Renal Cell Carcinoma – Current Treatment – Detailed, Expanded Analysis (EU5)

The treatment landscape for advanced/metastatic renal cell carcinoma includes well-established angiogenesis and mTOR inhibitors, many of which have broad labels allowing their use across several treatment settings. The approval of the first PD-1 inhibitor in this indication, Opdivo, has begun to have a significant impact on the treatment algorithm, particularly in later-line disease settings.

Table of contents

  • Renal Cell Carcinoma - Current Treatment - Detailed, Expanded Analysis (EU5)
    • Physician Prescribing Practices
      • Key Findings
      • Patient Characteristics
        • Majority of Newly Diagnosed Renal Cell Carcinoma Patients Managed by Medical Oncologists Present with Advanced or Metastatic Disease
        • Initial Diagnosis by Stage of Disease
        • Sites of First Metastases in Renal Cell Carcinoma
        • Use of Risk Assessment for Stage I-III Renal Cell Carcinoma
        • Risk Classification in Stage I-III Renal Cell Carcinoma
      • Treatment Practices: Newly Diagnosed Patients
        • Sutent Is the Patient Share Leader in Newly Diagnosed First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Antineoplastic Drug Therapy Is the Standard Treatment Option for Newly Diagnosed Advanced/Metastatic Renal Cell Carcinoma Patients
        • Newly Diagnosed Advanced/Metastatic Renal Cell Carcinoma Patients Receiving Treatment
        • Radical Nephrectomy Is the Most Common Nonpharmacological Treatment for Newly Diagnosed Locally Advanced Renal Cell Carcinoma Patients
        • Nonpharmacological Approaches for Newly Diagnosed Renal Cell Carcinoma Patients
        • Sutent Is the Patient-Share Leader in the First-Line Advanced/Metastatic Renal Cell Carcinoma Setting
        • Patient Share in Newly Diagnosed First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Average Duration of Treatment for First-Line Sutent and Votrient in Newly Diagnosed Advanced/Metastatic Renal Cell Carcinoma Is 11 Months
        • Treatment Duration in Newly Diagnosed First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Votrient Enjoys the Highest Compliance Rate Among All Therapies for Newly Diagnosed First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Compliance Rate in Newly Diagnosed First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Therapy Discontinuation Rate in Newly Diagnosed First-Line Advanced/Metastatic Renal Cell Carcinoma Patients
        • A Significantly Higher Percentage of Locally Advanced vs. Localized Renal Cell Carcinoma Patients Relapse to Metastatic Disease
        • Disease Progression in Newly Diagnosed Renal Cell Carcinoma Patients
      • Treatment Practices: Recurrent Patients
        • Drug Treatment Is Typically Administered to Recurrent Renal Cell Carcinoma Patients
        • Drug-Treatment Rates for Recurrent Advanced/Metastatic Renal Cell Carcinoma Decline in Later Lines of Treatment
        • Recurrent Advanced/Metastatic Renal Cell Carcinoma Patients Receiving Treatment
        • The Majority of Recurrent Advanced/Metastatic Renal Cell Carcinoma Patients Do Not Receive Nonpharmacological Treatment
        • Nonpharmacological Approaches for Recurrent Renal Cell Carcinoma Patients
        • Sutent Captures the Highest Patient Share in First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Patient Share in Recurrent Advanced/Metastatic Renal Cell Carcinoma
        • Actual Treatment Durations Are Shorter Than Those Intended Across All Lines of Therapy
        • Treatment Duration in Recurrent First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Treatment Duration in Recurrent Second-Line Advanced/Metastatic Renal Cell Carcinoma
        • Treatment Duration in Recurrent Third-Line Advanced/Metastatic Renal Cell Carcinoma
        • Therapy Compliance Rates Decrease as Patients Progress Through Lines of Treatment
        • Compliance Rate in Recurrent Advanced/Metastatic Renal Cell Carcinoma
        • Mortality During Treatment Increases in Later Lines of Treatment
        • Disease Progression in Recurrent Renal Cell Carcinoma
      • Sequencing of Treatment
        • An Optimal Treatment Sequence in Advanced/Metastatic Renal Cell Carcinoma Is Not Established
        • Sequencing of Treatment for Advanced/Metastatic Renal Cell Carcinoma Patients
      • Recent/Anticipated Changes in Brand Usage/Treatment Approach
        • Prescribing of Votrient and Inlyta Is Increasing for Treatment of Advanced/Metastatic Renal Cell Carcinoma
        • Changes in Treatment Approach: First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Changes in Treatment Approach: Second-Line Advanced/Metastatic Renal Cell Carcinoma
        • Changes in Treatment Approach: Third-Line Advanced/Metastatic Renal Cell Carcinoma
        • Statement Agreement
    • Physician Insight on Medical Practice
      • Key Findings
      • Drivers of Treatment Selection
        • Efficacy and Treatment-Related Side Effects Heavily Influence Therapy Selection in First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Efficacy Is the Major Driver of Physician Prescribing in First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Major Drivers of Brand Usage/Treatment: Sutent
        • Major Drivers of Brand Usage/Treatment: Votrient
        • Major Drivers of Brand Usage/Treatment: Nexavar
        • Major Drivers of Brand Usage/Treatment: Inlyta
        • Major Drivers of Brand Usage/Treatment: Torisel
        • Major Drivers of Brand Usage/Treatment: Afinitor
        • High Incidence of Grade 3/4 Adverse Events Is the Main Obstacle to Prescribing in First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Major Obstacles to Brand Usage/Treatment: Sutent
        • Major Obstacles to Brand Usage/Treatment: Votrient
        • Major Obstacles to Brand Usage/Treatment: Nexavar
        • Major Obstacles to Brand Usage/Treatment: Inlyta
        • Major Obstacles to Brand Usage/Treatment: Torisel
        • Major Obstacles to Brand Usage/Treatment: Afinitor
        • Treatment-Related Adverse Effects Is a Major Factor for Treatment Discontinuation in First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Rationale for Therapy Discontinuation: Sutent
        • Rationale for Therapy Discontinuation: Votrient
        • Rationale for Therapy Discontinuation: Nexavar
        • Rationale for Therapy Discontinuation: Inlyta
        • Rationale for Therapy Discontinuation: Torisel
        • Rationale for Therapy Discontinuation: Afinitor
      • Face-to-Face Product Detailing Effectiveness
        • Detailing Visits for Key Advanced/Metastatic Renal Cell Carcinoma Therapies Are frequent and Effective
        • The Majority of Surveyed Oncologists Had Contact with a Sales Representative for Key First-Line Advanced/Metastatic Renal Cell Carcinoma Therapies
        • Face-to-Face Product Detailing
        • Sales Representative Satisfaction Ratings Are High for All Advanced/Metastatic Renal Cell Carcinoma Therapies
        • Satisfaction with Sales Representatives' Knowledge of Therapies for Advanced/Metastatic Renal Cell Carcinoma
        • Satisfaction with Sales Representatives' Ability to Address Questions
        • Satisfaction with Sales Representatives' Overall Effectiveness in Bringing Value to Physician's Practice
        • Most Common Topic Discussed in Recent Sales Representative Visits Was Efficacy
        • Topics Discussed During Most Recent Sales Representative Visit
    • Appendix
      • Physician Prescribing Practices
        • Newly Diagnosed Advanced/Metastatic Renal Cell Carcinoma Patients Receiving Treatment: France
        • Newly Diagnosed Advanced/Metastatic Renal Cell Carcinoma Patients Receiving Treatment: Germany
        • Newly Diagnosed Advanced/Metastatic Renal Cell Carcinoma Patients Receiving Treatment: Italy
        • Newly Diagnosed Advanced/Metastatic Renal Cell Carcinoma Patients Receiving Treatment: Spain
        • Newly Diagnosed Advanced/Metastatic Renal Cell Carcinoma Patients Receiving Treatment: United Kingdom
        • Nonpharmacological Approaches for Newly Diagnosed Renal Cell Carcinoma Patients: France
        • Nonpharmacological Approaches for Newly Diagnosed Renal Cell Carcinoma Patients: Germany
        • Nonpharmacological Approaches for Newly Diagnosed Renal Cell Carcinoma Patients: Italy
        • Nonpharmacological Approaches for Newly Diagnosed Renal Cell Carcinoma Patients: Spain
        • Nonpharmacological Approaches for Newly Diagnosed Renal Cell Carcinoma Patients: United Kingdom
        • Treatment Duration in Newly Diagnosed First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Compliance Rate in Newly Diagnosed First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Therapy Discontinuation Rate in Newly Diagnosed First-Line Advanced/Metastatic Renal Cell Carcinoma: Country-Specific
        • Disease Progression in Newly Diagnosed Renal Cell Carcinoma: France
        • Disease Progression in Newly Diagnosed Renal Cell Carcinoma: Germany
        • Disease Progression in Newly Diagnosed Renal Cell Carcinoma: Italy
        • Disease Progression in Newly Diagnosed Renal Cell Carcinoma: Spain
        • Disease Progression in Newly Diagnosed Renal Cell Carcinoma: United Kingdom
        • Recurrent Advanced/Metastatic Renal Cell Carcinoma Patients Receiving Treatment: France
        • Recurrent Advanced/Metastatic Renal Cell Carcinoma Patients Receiving Treatment: Germany
        • Recurrent Advanced/Metastatic Renal Cell Carcinoma Patients Receiving Treatment: Italy
        • Recurrent Advanced/Metastatic Renal Cell Carcinoma Patients Receiving Treatment: Spain
        • Recurrent Advanced/Metastatic Renal Cell Carcinoma Patients Receiving Treatment: United Kingdom
        • Nonpharmacological Approaches for Recurrent Renal Cell Carcinoma Patients: France
        • Nonpharmacological Approaches for Recurrent Renal Cell Carcinoma Patients: Germany
        • Nonpharmacological Approaches for Recurrent Renal Cell Carcinoma Patients: Italy
        • Nonpharmacological Approaches for Recurrent Renal Cell Carcinoma Patients: Spain
        • Nonpharmacological Approaches for Recurrent Renal Cell Carcinoma Patients: United Kingdom
        • Patient Share for Recurrent Advanced/Metastatic Renal Cell Carcinoma: France
        • Patient Share for Recurrent Advanced/Metastatic Renal Cell Carcinoma: Germany
        • Patient Share for Recurrent Advanced/Metastatic Renal Cell Carcinoma: Italy
        • Patient Share for Recurrent Advanced/Metastatic Renal Cell Carcinoma: Spain
        • Patient Share for Recurrent Advanced/Metastatic Renal Cell Carcinoma: United Kingdom
        • Treatment Duration in Recurrent First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Treatment Duration in Recurrent Second-Line Advanced/Metastatic Renal Cell Carcinoma
        • Treatment Duration in Recurrent Third-Line Advanced/Metastatic Renal Cell Carcinoma
        • Compliance Rate in Recurrent First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Compliance Rate in Recurrent Second-Line Advanced/Metastatic Renal Cell Carcinoma
        • Compliance Rate in Recurrent Third-Line Advanced/Metastatic Renal Cell Carcinoma
        • Disease Progression in Recurrent Renal Cell Carcinoma
        • Changes in Treatment Approach: First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Changes in Treatment Approach: Second-Line Advanced/Metastatic Renal Cell Carcinoma
        • Changes in Treatment Approach: Third-Line Advanced/Metastatic Renal Cell Carcinoma
        • Statement Agreement: France
        • Statement Agreement: Germany
        • Statement Agreement: Italy
        • Statement Agreement: Spain
        • Statement Agreement: United Kingdom
      • Physician Insight on Medical Practice
        • Face-to-Face Product Detailing: France (Sales Representative Frequency and Reach)
        • Face-to-Face Product Detailing: Germany
        • Face-to-Face Product Detailing: Italy
        • Face-to-Face Product Detailing: Spain
        • Face-to-Face Product Detailing: United Kingdom
        • Mean Satisfaction Ratings for Sales Representative Attributes
        • Mean Satisfaction Ratings for Sales Representative Attributes: France
        • Mean Satisfaction Ratings for Sales Representative Attributes: Germany
        • Mean Satisfaction Ratings for Sales Representative Attributes: Italy
        • Mean Satisfaction Ratings for Sales Representative Attributes: Spain
        • Mean Satisfaction Ratings for Sales Representative Attributes: United Kingdom